OptimizeRx names Andy D'Silva CFO effective Jan. 1, 2027

• OptimizeRx named Andy D'Silva chief financial officer, effective Jan. 1, 2027, succeeding Ed Stelmakh.
• D'Silva previously served as chief business officer, covering financial strategy, capital allocation, investor relations, corporate development, long-range planning.
• Heather Favazza was appointed chief accounting officer, effective Jan. 1, 2027.
• Favazza has served as corporate controller for eight years, overseeing accounting operations, financial reporting, internal controls, compliance.
• Stelmakh will remain chief financial and strategy officer through Dec. 31, 2026, then serve as strategic adviser through end-2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. OptimizeRx Corporation published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608121605PRIMZONEFULLFEED9808249) on August 12, 2026, and is solely responsible for the information contained therein.